Compare IQV & MSCI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IQV | MSCI |
|---|---|---|
| Founded | 1982 | 1998 |
| Country | United States | United States |
| Employees | 93000 | N/A |
| Industry | Biotechnology: Commercial Physical & Biological Resarch | Business Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 43.1B | 41.6B |
| IPO Year | 2013 | 2007 |
| Metric | IQV | MSCI |
|---|---|---|
| Price | $270.87 | $552.59 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 16 | 9 |
| Target Price | $227.13 | ★ $682.44 |
| AVG Volume (30 Days) | ★ 1.3M | 457.4K |
| Earning Date | 05-05-2026 | 04-21-2026 |
| Dividend Yield | N/A | ★ 1.37% |
| EPS Growth | 4.67 | ★ 11.67 |
| EPS | 1.61 | ★ 10.23 |
| Revenue | ★ $9,739,000,000.00 | $1,274,172,000.00 |
| Revenue This Year | $6.77 | $12.56 |
| Revenue Next Year | $5.89 | $8.39 |
| P/E Ratio | $170.82 | ★ $54.36 |
| Revenue Growth | ★ 41.60 | N/A |
| 52 Week Low | $154.50 | $501.08 |
| 52 Week High | $277.40 | $644.77 |
| Indicator | IQV | MSCI |
|---|---|---|
| Relative Strength Index (RSI) | 62.05 | 46.59 |
| Support Level | $159.91 | $546.19 |
| Resistance Level | $271.80 | $573.67 |
| Average True Range (ATR) | 6.37 | 12.16 |
| MACD | -0.65 | 0.82 |
| Stochastic Oscillator | 73.64 | 49.94 |
Iqvia is a global leader in clinical research and technology solutions for the life science industry. Formed in 2016 from the merger of Quintiles and IMS Health, it combined clinical trial services with extensive healthcare data and analytics. Its research and development solutions segment provides outsourced clinical development services spanning drug discovery, trial design, patient recruitment, site management, clinical testing, real-world studies, and the regulatory approval process. Its commercial solutions segment helps companies optimize product commercialization through analytics, technology, and outsourced sales and medical services. Together, Iqvia supports customers across the life science industry, and it serves biopharmaceutical firms, providers, payers, and policymakers.
MSCI has described its mission as enabling investors to build better portfolios for a better world. MSCI's largest and most profitable segment is its index segment, where it provides benchmarking to asset managers and asset owners. MSCI boasts over $18 trillion (as of December 2025) in benchmarked assets, including over $2.3 trillion in ETF assets linked to MSCI indexes. The MSCI analytics segment provides portfolio management and risk management analytics software to asset managers and asset owners. In its sustainability and climate segment, MSCI provides ESG data to the investment industry. In private assets, MSCI provides real restate reporting, market data, benchmarking, and analytics to investors and real estate managers.